Allurion Technologies’ (ALUR) Neutral Rating Reaffirmed at Chardan Capital

Allurion Technologies (NYSE:ALUR)‘s stock had its “neutral” rating reaffirmed by analysts at Chardan Capital in a note issued to investors on Thursday,Benzinga reports. They presently have a $2.50 price objective on the stock. Chardan Capital’s price objective would suggest a potential downside of 25.37% from the company’s previous close. Chardan Capital also issued estimates for Allurion Technologies’ FY2025 earnings at ($4.39) EPS.

Separately, Roth Mkm reissued a “buy” rating and issued a $16.00 target price on shares of Allurion Technologies in a report on Friday, March 21st.

Allurion Technologies Price Performance

Shares of NYSE ALUR opened at $3.35 on Thursday. Allurion Technologies has a 1 year low of $2.15 and a 1 year high of $98.75. The firm has a fifty day moving average price of $4.01 and a 200-day moving average price of $9.89. The stock has a market cap of $16.06 million, a PE ratio of -0.28 and a beta of -0.59.

Institutional Trading of Allurion Technologies

A hedge fund recently raised its stake in Allurion Technologies stock. Geode Capital Management LLC grew its position in Allurion Technologies Inc. (NYSE:ALUR) by 40.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 516,330 shares of the company’s stock after acquiring an additional 149,484 shares during the quarter. Geode Capital Management LLC owned about 0.80% of Allurion Technologies worth $317,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 21.39% of the company’s stock.

Allurion Technologies Company Profile

Allurion Technologies Inc focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite.